DUBLIN–(BUSINESS WIRE)–The “Erectile
Dysfunction Drugs Market: Global Industry Analysis, Trends, Market Size,
and Forecasts up to 2024” report has been added to ResearchAndMarkets.com’s
offering.
The report predicts the global erectile dysfunction drugs market to grow
with a CAGR of 6.8% over the forecast period from 2018-2024.
The study on erectile dysfunction drugs market covers the analysis of
the leading geographies such as North America, Europe, Asia-Pacific, and
RoW for the period of 2016 to 2024. The report on the global erectile
dysfunction drugs market provides qualitative and quantitative analysis
for the period from 2016 to 2024.
The report on erectile dysfunction drugs market is a comprehensive study
and presentation of drivers, restraints, opportunities, demand factors,
market size, forecasts, and trends in the global erectile dysfunction
drugs market over the period of 2016 to 2024. Moreover, the report is a
collective presentation of primary and secondary research findings.
Porter’s five forces model in the report provides insights into the
competitive rivalry, supplier and buyer positions in the market and
opportunities for the new entrants in the global erectile dysfunction
drugs market over the period of 2016 to 2024. Further, the Growth Matrix
gave in the report brings an insight into the investment areas that
existing or new market players can consider.
Report Findings
Drivers
- Rising incidences of chronic diseases
- Growing changes in lifestyle and eating habits
- Increasing geriatric population
Restraints
- Risk of side effects caused from erectile dysfunction drugs
- Expiration of patents
Opportunities
- Increasing awareness about cures for erectile dysfunction
- Emergence of generic drugs and new drug delivery techniques
What does this report deliver?
1. Comprehensive analysis of the global as well as regional markets of
the erectile dysfunction drugs market.
2. Complete coverage of all the segments in the erectile dysfunction
drugs market to analyze the trends, developments in the global market
and forecast of market size up to 2024.
3. Comprehensive analysis of the companies operating in the global
erectile dysfunction drugs market. The company profile includes analysis
of product portfolio, revenue, SWOT analysis and latest developments of
the company.
4. Growth Matrix presents an analysis of the product segments and
geographies that market players should focus to invest, consolidate,
expand and/or diversify.
Topics Covered
1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches
2. Executive Summary
2.1. Erectile Dysfunction Drugs Market Highlights
2.2. Erectile Dysfunction Drugs Market Projection
2.3. Erectile Dysfunction Drugs Market Regional Highlights
3. Global Erectile Dysfunction Drugs Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Porter’s Five Forces Analysis
3.4. Growth Matrix Analysis
3.4.1. Growth Matrix Analysis by Drug
3.4.2. Growth Matrix Analysis by Mode of Administration
3.4.3. Growth Matrix Analysis by End-User
3.4.4. Growth Matrix Analysis by Region
3.5. Value Chain Analysis of Erectile Dysfunction Drugs Market
4. Erectile Dysfunction Drugs Market Macro Indicator Analysis
5. Global Erectile Dysfunction Drugs Market by Drug
5.1. Sildenafil (Viagra)
5.2. Tadalafil (Cialis)
5.3. Vardenafil (Levitra, Staxyn)
5.4. Avanafil (Stendra)
5.5. Muse Suppository (alprostadil)
5.6. Others
6. Global Erectile Dysfunction Drugs Market by Mode of
Administration
6.1. Oral
6.2. Topical
6.3. Injections
6.4. Others
7. Global Erectile Dysfunction Drugs Market by End-User
7.1. Hospital Pharmacies
7.2. Retail Pharmacies
7.3. Online Pharmacies
8. Global Erectile Dysfunction Drugs Market by Region 2018-2024
8.1. North America
8.2. Europe
8.3. Asia-Pacific
8.4. RoW
9. Company Profiles and Competitive Landscape
9.1. Competitive Landscape in the Global Erectile Dysfunction Drugs
Market
9.2. Companies Profiled
9.2.1. Pfizer Inc.
9.2.2. Bayer AG
9.2.3. Eli Lilly & Co.
9.2.4. DONG-A PHARM
9.2.5. Apricus Biosciences Inc.
9.2.6. Vivus Inc.
9.2.7. Meda AB
9.2.8. SK Chemicals
9.2.9. Cristalia Produtos Quimicos Farmaceuticos Ltda.
9.2.10. Teva Pharmaceutical Industries Ltd.
For more information about this report visit https://www.researchandmarkets.com/research/43f2mz/global_erectile?w=4
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Sexual
and Reproductive Health Drugs